Clinical trial NCT02560051: Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
Official title: Phase 2 Study of Androgen Deprivation Therapy (ADT) Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Prostatic Neoplasms
Keywords: Prostate Cancer
Advanced
Local Failures
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
First posted: 2015-09-25
Enrollment: 19
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is for men who have prostate cancer and have failed local therapy or are not a candidate for prostatectomy or radiation therapy. The purpose of this research study is to assess the safety and benefit of androgen deprivation therapy (ADT, blocks hormones) plus chemotherapy. Degarelix is the hormone blocking drug that will be used. Doxorubicin, Ketoconazole, Docetaxel and Estramustine are the chemotherapy drugs that will be used. The drugs used in this study are approved by the Food and Drug Administration (FDA).

Participants will be treated with ADT plus chemotherapy for three, four, or five 8-week cycles (12, 18, or 24 months). The number of cycles of chemotherapy they receive and the number of months they receive ADT will be based on their disease. The current standard treatment is ADT and chemotherapy. What differs in this research study is the cycling and combination of chemotherapy drugs chosen. The drugs chosen for this study have fewer side effects and are believed to provide maximum benefit.

Detailed description: As a working hypothesis, investigators suspect that the transformation from an androgen-dependent to an androgen-independent phenotype is mediated by expansion of an androgen-independent clone already present at the time of ADT that continues to grow while androgen-sensitive clones are being suppressed. It is thus desirable to bring treatment to bear on the androgen-independent component while the corresponding tumor burden remains minimal and prolong the time to hormone resistance. Investigators view the androgen-independent component as analogous to "microscopic residual" or "micro-metastatic" disease, for which adjuvant chemotherapy has been shown to be effective in other contexts, even when the same drugs had little or no impact on survival in the setting of more advanced disease.

By treating all components of the tumor initially, investigators anticipate that the emergence of androgen-independent growth will be delayed, ultimately prolonging patient survival. Additionally, instead of treating patients empirically with an identical regimen, as in investigator's previous work, these patient subsets were designed to ensure a level of treatment appropriate to their individual disease, thus potentially lessening the burden of treatment (such as the long-term adverse effects of ADT). Investigators have chosen 3, 4, or 5 cycles of chemotherapy to be administered on the basis of tumor burden, a treatment selection method long established in germ cell tumors and used by this PI. Sub-analyses of previous data have raised the concern that treating patients with varying levels of disease the same way does not produce optimal results. Therefore, investigators seek to improve outcomes by tailoring treatment to tumor burden. In this study, patients with less tumor burden will receive 3 cycles of chemotherapy and 12 months of ADT, those with moderate tumor burden will receive 4 cycles and 18 months of treatment, and those with the greatest tumor burden will receive 5 cycles and 24 months of treatment. Additionally, this regimen of administering treatment sequentially, including a 2-week break, reduces toxicity.

Eligibility criteria: Inclusion criteria:

* Pathologic proof of adenocarcinoma of the prostate.
* Patients must belong to one of the following subsets:
* Prior local therapy
* Patients with Prostate Specific Antigen (PSA) recurrence following prostatectomy or radiation therapy who have no radiographic involvement. PSA doubling time ≤6 months.
* Nodal involvement only.
* Low volume bone disease: ≤3 metastases.
* Nodal involvement with associated bone involvement.
* High volume bone-visceral disease: Patients with \>3 metastatic bone sites or visceral metastases.
* No prior definitive local therapy
* Tumors felt to be unresectable, not candidates for radiation therapy, and PSA elevated with biopsy-proven disease.
* Metastatic disease at presentation.
* Patients may have started ADT within 3 months of study entry.
* No previous cytotoxic therapy is allowed, including systemic irradiation with strontium-89, samarium, or radium-223.
* Previous definitive radiotherapy to one metastatic site is acceptable, provided that unirradiated sites remain. At least 8 weeks must have elapsed since radiation therapy to the pelvis. Patients having limited irradiation of a metastatic site are eligible 4 weeks following radiation.
* Patients may have had previous exposure to ADT if it was given for ≤6 months to "downstage" the primary and provided that such therapy was completed at least 12 months prior to entry into this study with a return of serum testosterone to ≥200 ng/dL.
* Patients must be free of serious comorbidity and have a life expectancy of ≥3 years.
* Patients must have adequate physiologic reserves as evidenced by:
* Eastern Cooperative Oncology Group (ECOG) status of ≤2.
* Patients must have adequate bone marrow function: Platelets ≥100,000 cells/mm3, Hemoglobin ≥9.0 g/dL, and Absolute Neutrophil Count (ANC) ≥1,500 cells/mm3.
* Patients must have adequate renal function: creatinine ≤2 × upper limit of normal (ULN).
* Patients must have adequate liver function: Aspartate aminotransferase (AST) / Alanine transaminase (ALT) ≤2.5 × ULN; alkaline phosphatase \<2.5 × ULN, unless bone metastasis is present in the absence of liver metastasis; and bilirubin \< ULN or 1.5 mg/dl.
* No evidence of active ischemia on electrocardiogram (ECG) and documentation of ejection fraction (EF) ≥50%.

Exclusion criteria:

* Patients must not have a second malignancy unless there is confidence of previous curative therapy.
* Patients with a recent history of transient ischemic attack (TIA) (within 6 months), who are requiring regular antianginal therapy, or who are having claudication sufficient to limit activity are not eligible. Patients with a previous history of deep venous thrombosis or pulmonary embolism (within 12 months) are not eligible
* Patients must not have a serious intercurrent medical or psychiatric illness, including serious active infection.
* Patients must not have sensory neuropathy \> grade 1.

Primary outcomes:
measure: Efficacy as Measured by Number Who Progressed
timeFrame: From the time the participant signs the informed consent until the participant was taken off-study or the study was stopped, an average of 10 months
Secondary outcomes:
measure: Efficacy as Measured by Number of Participants With Pathology/Biopsy Positive for Disease
timeFrame: about 10 months after treatment initiation
measure: Efficacy as Measured by PSA Level
timeFrame: baseline
measure: Efficacy as Measured by PSA Level
timeFrame: Cycle 1 Day 1, which is the day of treatment initiation
measure: Efficacy as Measured by PSA Level
timeFrame: Cycle 2 Day 1, which is about 8 weeks after treatment initiation
measure: Efficacy as Measured by PSA Level
timeFrame: Cycle 3 Day 1, which is about 16 weeks after treatment initiation
measure: Efficacy as Measured by PSA Level
timeFrame: Cycle 4 Day 1, which is about 24 weeks after treatment initiation
measure: Efficacy as Measured by PSA Level
timeFrame: Cycle 5 Day 1, which is about about 32 weeks after treatment initiation
measure: Efficacy as Measured by PSA Level
timeFrame: end of treatment, which is about about 8 weeks after the start of the last cycle
measure: Efficacy as Measured by Number Who PSA Progressed
timeFrame: From the time the participant signs the informed consent until the participant was taken off-study or the study was stopped, an average of 10 months
measure: Quality of Life Measure by FACT-P Scale
timeFrame: post cycle 1, which is about 8 weeks after treatment initiation
measure: Quality of Life Measure by FACT-P Scale
timeFrame: post cycle 2, which is about 16 weeks after treatment initiation
measure: Quality of Life Measure by FACT-P Scale
timeFrame: post cycle 3, which is about 24 weeks after treatment initiation
measure: Quality of Life Measure by FACT-P Scale
timeFrame: post cycle 4, which is about 32 weeks after treatment initiation
measure: Quality of Life Measure by FACT-P Scale
timeFrame: post cycle 5, which is about about 40 weeks after treatment initiation
measure: Quality of Life Measure by FACT-P Scale
timeFrame: about 12 weeks after completion of the last cycle
measure: Safety of Drug Regimen as Measured by Number of Adverse Events
timeFrame: From the time the participant signs the informed consent until the participant was taken off-study or the study was stopped, an average of 10 months
Other outcomes:
Locations:
city: Houston
country: United States
facility: UTHealth Memorial Hermann Cancer Center
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center, Houston
name: Robert J Amato, DO
role: PRINCIPAL_INVESTIGATOR
References: